Ibn Sina's Canon of Medicine and modern supplement science

A book that taught medicine in Europe for 600 years

Abu Ali al-Husayn ibn Sina — known in Europe as Avicenna — wrote his Al-Qanun fi at-Tibb (The Canon of Medicine) around 1025 CE, in his late thirties. The five-volume work was the standard medical textbook in European universities from the 12th century until the 17th. Latin manuscripts of the Canon were still being printed in Padua and Bologna as late as 1670. There is no medical text from any tradition with a longer continuous teaching record.

The Canon is many things at once: a theory of physiology rooted in the Galenic four-humours system, an experimental pharmacology with over 800 simple medicines catalogued by their properties, a methodology for clinical testing of new compounds (Ibn Sina laid out seven rules for trialing new drugs, four of which would not look out of place in a 2026 GCP protocol), and a synthesis of the Greek, Persian, and Indian medical traditions that had reached Baghdad by the 11th century.

For our purposes — formulating a halal supplement in Manchester in 2026 — the Canon matters because it is where the apothecary tradition we draw on most directly was systematised.

What Ibn Sina did that nobody had quite done before

Three things separate the Canon from what came before it:

1. Standardisation of medicines. Ibn Sina insisted that simple medicines (single botanicals) be described not just by name but by their preparation — water-extracted, oil-extracted, the part of the plant used, the season collected. He understood — without modern analytical chemistry — that the active compound concentration varies with all of these variables. Today we call this "standardisation to active compound percentage." Ibn Sina was doing the qualitative version a thousand years ago.

2. Trial methodology. Book II of the Canon contains a seven-rule protocol for trialing a new medicine: the drug must be free of acquired qualities (no adulteration); the condition treated must be simple (no comorbidities); the drug must be tested against two opposing conditions to rule out coincidence; the dose must be proportionate to the disease; observation must be over time; effect must be consistent across many cases; and the trial must be on humans, since animal response does not reliably predict human response.

The seventh rule is what surprises modern readers most. Ibn Sina was rejecting animal-only pharmacology in 1025. The contemporary clinical trial protocol arrives at the same conclusion roughly 950 years later.

3. Cataloguing. Books III and IV of the Canon describe hundreds of compound medicines (mixed formulations) by their ingredient list and indicated use. The closest modern analogue is the British Pharmacopoeia. Ibn Sina's was first compiled in his early twenties.

Where IH draws from the Canon directly

Three ingredients in The Barakah Pill have direct Avicennian lineage:

Black seed (Nigella sativa). Catalogued in the Canon as habba al-sawda*. Ibn Sina describes its use for chest conditions, digestive support, and as a general restorative. Modern lab analysis identifies thymoquinone as the principal active compound. We use it at the level used in the published research standardised to its principal active thymoquinone.

Saffron (Crocus sativus). Catalogued under za'faran*. Ibn Sina describes mood-elevating and circulatory effects, and provides the first known description of saffron's standardised preparation as a tincture. Modern research isolates Lepticrosalides as the active compound class. We use it at the level used in the published research standardised our clinically characterised saffron extract — the same dose used in the most-cited modern clinical work.

Fenugreek (Trigonella foenum-graecum). Catalogued under hulba*. Ibn Sina describes its use in restorative tonics. Modern research isolates Fenuside saponins. We use the clinically characterised standardised extract at the level used in the published research.

What we don't draw from the Canon

We don't draw the Galenic four-humours theory of physiology — phlegm, blood, yellow bile, black bile. That model was superseded in the 17th century and we mean it when we say "supplement science" not "humoral medicine." When the historical record and the modern published research diverge, we follow the research.

This is the apothecary tradition's strength: it was always self-correcting. Ibn al-Qayyim's At-Tibb an-Nabawi explicitly distinguishes between the divinely-revealed dietary guidance (which is binding on Muslims) and the medical theory of his day (which he treats as the best contemporary understanding, subject to revision). The same posture applies in 2026.

Why this matters for IH

When a customer asks why we put saffron in The Barakah Pill at the level used in the published research — not below or above the published level — the answer is twofold:

Both halves matter. Without the first half (modern research), the second half (heritage) is folkloric. Without the second half, the first half is decontextualised — there is no reason to choose this ingredient over another. The intersection is where considered formulation lives.

A reading list

If you want to read further:

For the modern research on Ibn Sina specifically, the 2009 special issue of the Journal of the International Society for the History of Islamic Medicine (JISHIM Vol. 8) remains the best single reference.